Once-daily oral dosing of AM-9747 demonstrated a reductionin the SDMA tumor biomarker, resulting in effective tumor growth inhibitionand tumor regression when examined in various MTAP-del xenograft models.These results laid the foundation for our subsequent PRMT5 research,leading to AMG 193, the first MTA-cooperative PRMT5 forclinical evaluation, currently in Phase I/II clinical trials for thetreatment of advanced MTAP-null solid tumors (NCT05094336 and NCT05975073). This evidence concerns the gene PRMT5 and neoplasm.